Abbott Zyflo mechanism of action differs from Zeneca's Accolate, company explains.
Executive Summary
ABBOTT ZYFLO MECHANISM OF ACTION DIFFERS FROM ZENECA's ACCOLATE; while both asthma products act on the leukotriene pathway, Abbott's zileuton inhibits the formation of leukotrienes while Zeneca's zafirlukast blocks the action of already formed leukotrienes. Labeling describes Zyflo as a "leukotriene inhibitor," while Accolate is called a "leukotriene antagonist." [Editors' note: In its coverage of the Dec. 9 approval of Zyflo, "The Pink Sheet" (Dec. 16, p. 21) used the terms leukotriene "inhibitor" and "antagonist" interchangeably .]